# June Quarterly Shareholder Update

Gary Phillips, CEO

# FORWARD LOOKING STATEMENT

This document contains forward-looking statements, including statements concerning Syntara's future financial position, plans, and the potential of its products and product candidates, which are based on information and assumptions available to Syntara as of the date of this document. Actual results, performance or achievements could be significantly different from those expressed in, or implied by, these forward-looking statements. All statements, other than statements of historical facts, are forward-looking statements.

These forward-looking statements are not guarantees or predictions of future results, levels of performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results to differ materially from those expressed in the statements contained in this document. For example, despite our efforts there is no certainty that we will be successful in developing or partnering any of the products in our pipeline on commercially acceptable terms, in a timely fashion or at all. Except as required by law we undertake no obligation to update these forward-looking statements as a result of new information, future events or otherwise.

# June Quarter 2026 - Highlights

- **Positive US FDA feedback supports the proposed clinical development pathway via Phase 2b trial of amsulostat in myelofibrosis**
- **$8.0 million institutional placement strengthens balance sheet and extends expected cash runway into FY28**
- **Subsequent to the end of the quarter:**
  - **Preliminary Phase 2 SNT-4728 results show a statistically significant reduction in inflammation within a key Parkinson's disease-related brain region**
  - **SNT-9465 Phase 1b hypertrophic scar trial reaches 60% treatment commencement, with recruitment completion targeted for Q3 2026**
  - **AZALOX MDS study advances to final Phase 1b dose cohort**
- **Multiple clinical catalysts expected in H2 2026, including complete SNT-4728 data, amsulostat MDS interim results and SNT-9465 top-line results**

# SHAREHOLDERS & CASH

| Financial Information (ASX: SNT) | |
|---|---|
| Share price – 23 July 2026 | $0.024 |
| Market cap | A$47m |
| Cash balance (30 Jun 2026) | A$13.5m |
| Enterprise value | A$33.5m |

| Institutional Ownership | 30 Jun 26 |
|---|---|
| D&A Income Limited | 18% |
| Platinum Investment Management Limited | 12% |
| **Total Institutional Ownership** | **> 44%** |

| Research Coverage | |
|---|---|
| Canaccord Genuity | Euroz Hartleys |
| Bell Potter | Evolution Capital |

## Share Price & Volume - YTD


* 11 August 2025 recorded volume was 119,820,710 following announcement of FDA guidance for amsulostat

# THREE ASSETS CREATE MULTIPLE PATHS TO VALUE

## A diversified clinical-stage pipeline across blood cancers, fibrosis and neurodegenerative disease

| ASSET | INDICATION | TOTAL ADDRESSABLE MARKET | DEVELOPMENT STATUS |
|---|---|---|---|
|  **amsulostat** | **Haematological malignancies** | Myelofibrosis: ~US$2.8b p.a.<br>Myelodysplastic syndrome: ~US$3.2b p.a. | • Phase 2a clinical proof of concept in MF - complete<br>• FDA-aligned planned Phase 2b pathway – Q4 26 start<br>• AZALOX and MESSAGE MDS studies – preliminary data Q4 26 |
|  **SNT-9465** | **Fibrosis and skin scarring** | Global scar-treatment market projected to reach US$50–55b by 2030. | • Hypertrophic-scar Phase 1b program – recruiting<br>• Top-line safety and efficacy data targeted in H2 2026. |
|  **SNT-4728** | **Parkinson's disease and iRBD** | Global Parkinson's disease market expected to reach US$7.6b by 2030. | • Phase 2 iRBD/Parkinson's program – preliminary data reported<br>• Final study results in Q3 2026. |

# SUMMARY AND NEXT STEPS

## Top-line Phase 2a data highlights amsulostat's potential in MF

### Improvements of 50% or more in total symptom score (TSS50)

were observed quickly (as early as 12 weeks) and were sustained, with 73% (8/11) of patients achieving TSS50 at Week 24 or beyond

### Meaningful spleen volume reductions (SVR) were observed

at 24 weeks and maintained thereafter, with 44% (4/9) of patients achieving SVR25 at Week 24 or beyond

### Of the 7 patients that completed 52 weeks of treatment

- 6 chose to continue on amsulostat through named patient supply
- 3 of these patients had a minor anaemia response
- 2 achieved a complete (100%) resolution of symptoms from baseline

### Differentiated TPP

- Competitive safety and efficacy profile in suboptimal MF JAKi patients
- Potential for disease modification and use in earlier stage MF
- Positive FDA review of Phase 2b trial protocol clears next stage of clinical development

**Next phase of development and study design for BRIDGE-MF guided by clinical advisory board and aligned with recent FDA feedback.**

# STRONG INTEREST IN MF ASSETS FROM STRATEGICS

| Target / Acquiror | KARTOS THERAPEUTICS / IPSEN | Ajax / Lilly | 中国生物制药有限公司 SINO BIOPHARMACEUTICAL LIMITED / sanofi | KEROS / Takeda | morphosys / NOVARTIS |
|---|---|---|---|---|---|
| **DATE OF ANNOUNCEMENT*** | **JULY-2026** | **APRIL-2026** | **MARCH-2026** | **DEC-2024** | **FEB-2024** |
| **Drug Name** | Navtemadlin | AJ1-11095 | Rovadicitinib | Elritercept | Pelabresib |
| **Lead Indication / Phase (at transaction)** | Myelofibrosis (ongoing Phase 3) | Myelofibrosis (ongoing Phase 1) | Myelofibrosis (completed Phase 2) | MDS and MF (ongoing Phase 2 trials) | Myelofibrosis (successful Phase 3 studies) |
| **Deal Type** | Acquisition | Acquisition | License | License | Acquisition |
| **Upfront / Milestones (US$)** | US$450M / US$1.3B | Total deal value US$2.3B | US$135M / US$1.395B | US$200M / US$1.1B | US$2.9B |
| **Earnout Payments / Royalty Rate (%)** | Not disclosed | Not disclosed | Not disclosed | Not disclosed | Subject to regulatory approvals |

**Attractive commercial outcomes for drugs with Phase 2 and 3 data expected to drive interest in amsulostat Phase 2 data**

SYNTARA

*** Prior to 2024:**
**SOBI acquisition of Pacritinib from CTI for US$1.7B**
**GSK acquisition of Momelotinib from Sierra Oncology for US$1.9B**

# AMSULOSTAT: A NEW FUTURE IN MF TREATMENT OPTIONS

## Aspirational lifecycle development in MF enabled by first in class pan-LOX mechanism

### Ideal add-on for patients with sub-optimal response to JAKi

- FDA endorsed phase 2b protocol
- Pan-lysyl oxidase inhibition mechanism and favourable tolerability support combination use with JAKi.
- Inhibition of LOX-mediated PDGFR signalling enhances impact of JAKi on cell proliferation.
- Potential to improve symptoms and extend the useful treatment duration of JAKi through effects on the bone marrow microenvironment

Market Opportunity ~$1b

### Potentially best positioned in frontline combination with JAKi

- Pan-lysyl oxidase inhibition mechanism and favourable tolerability profile makes amsulostat well suited for early combination use.
- Targeting fibrosis biology and microenvironmental signaling complements JAK inhibition.
- Early use maximises impact on symptoms, spleen response and longer-term disease biology.

Market Opportunity ~$1.8b

### Opportunity to slow progression in newly diagnosed MF

- Pan-lysyl oxidase inhibition may preserve and restore the bone microenvironment to slow disease progression.
- Strong tolerability supports use earlier in treatment paradigm, before patients become symptomatic.
- Potential for disease modification and improved survival is maximised when used early.

Market Opportunity ~$2.8b

# REDUCTION IN INFLAMMATION

## Statistically significant reduction in brain inflammation observed unilaterally in the putamen (p-value 0.0145)

- The putamen is a key region underlying the hallmark motor symptoms of Parkinson's disease.
- 20 out of 30 pts on active treatment (SNT-4728) recorded a reduction in inflammation from baseline.
- No statistically significant change in inflammation was detected in other predefined regions of interest.
- No significant reduction in brain inflammation in any region for placebo group.

| Putamen | Binding Potential ($BP_{ND}$) | | Mean change | P-value (Paired t-test) |
|---|---|---|---|---|
| | Mean at baseline | Mean at 12 weeks | | |
| Right | 0.002918 | -0.012073 | **-0.016 (0.033)** | **0.0145** |
| Left | -0.001209 | 0.001692 | 0.003 (0.029) | 0.6219 |




20/30 pts had reduced inflammation after 12 weeks treatment.




At week 12, inflammation significantly reduced compared to placebo.

$BP_{ND}$ is a dimensionless number expressing the distribution volume ratio of specifically bound radioligand to that of non-displaceable radioligand.

# INNOVATIVE TRIAL DESIGN TO EVALUATE COMMERCIAL VIABILITY

## Placebo controlled scar remodeling study with multiple efficacy readouts in H2 2026

**Healthy Volunteer Phase 1a Single Ascending Dose**

✓ Dose-dependent target engagement confirmed

**Hypertrophic scars Phase 1b Multiple Daily Dose**

Randomized, Double-blinded,
Placebo-controlled Split-scar Study in Adult Participants with Hypertrophic Sternotomy Scars (N=20)




### Trial design optimised for inclusion criteria and endpoints

**PRIMARY ENDPOINT**

- Safety TEAEs

**SECONDARY ENDPOINTS**

- Pharmacokinetics / Pharmacodynamics
- Scar rating (multiple blinded raters)
- 3D imaging (scar volume)
- Optical Coherence Tomography (OCT)
- Elastography
- Patient and Observer Scar Assessment Scale (POSAS)

# THE YEAR AHEAD - *POISED TO DELIVER NEAR TERM VALUE*

| TARGET | DRUG | INDICATION | PARTNERS | PHASE 1 | PHASE 2 | ANTICIPATED NEWS FLOW | |
|---|---|---|---|---|---|---|---|
| | | | | HEALTHY PARTICIPANTS | PATIENTS | H1 2026 | H2 2026 |
| Pan-LOX | Amsulostat (SNT-5505) | Myelofibrosis | | → | → | FDA approved development plan and partner engagement | Trial Progression |
| | | High Risk MDS AZALOX trial | Deutsche Krebshilfe | → | → | | Interim safety and efficacy data Phase 2 initiation |
| | | Low / Int Risk MDS MESSAGE trial | ALLG | → | → | | Interim safety and efficacy data |
| | | Pancreatic cancer FALCON trial | Garvan Institute of Medical Research | → | → | | Investigator Study TBD |
| Topical Pan-LOX | SNT-9465 | Hypertrophic scarring | | → | → | Recruit hypertrophic scar Phase 1b trial | Top Line safety and efficacy data |
| | SNT-6302 | Keloid scarring | University of Western Australia, Rona Wood Foundation | → | → | | Interim safety and efficacy data |
| Dual SSAO & MAO-B | SNT-4728 | IRBD / Parkinson's Disease | In partnership with Parkinson's UK | → | → | Phase 2 Top Line data | Phase 2 full results |

SYNTARA

MDS: Myelodysplastic Syndrome; Int: Intermediate; IRBD: Isolated REM sleep Behaviour Disorder

Gary Phillips
Chief Executive Officer
gary.phillips@syntaratx.com.au

Alison Findlay
Head Business Development & Licensing
alison.findlay@syntaratx.com.au

**http://syntaratx.com.au**